Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
Titel:
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment
Auteur:
Madorsky Rowdo, Florencia P. Xiao, Gu Khramtsova, Galina F. Nguyen, John Martini, Rachel Stonaker, Brian Boateng, Richard Oppong, Joseph K. Adjei, Ernest K. Awuah, Baffour Kyei, Ishmael Aitpillah, Frances S. Adinku, Michael O. Ankomah, Kwasi Osei-Bonsu, Ernest B. Gyan, Kofi K. Altorki, Nasser K. Cheng, Esther Ginter, Paula S. Hoda, Syed Newman, Lisa Elemento, Olivier Olopade, Olufunmilayo I. Davis, Melissa B. Martin, M. Laura Bargonetti, Jill